Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Slides:

Advertisements

Similar presentations

Surgical margins for melanoma in situ

Advertisements

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Robert Klein, MS, Catherine.

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients Noël Emile Célestin.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced.

Dermatology physician extenders: A new risk factor?

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Smoking and risk of psoriasis: A nationwide cohort study

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

Treatment of toxic epidermal necrolysis in North America

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Toxic epidermal necrolysis secondary to emergency contraceptive pills

Sally Helen Ibbotson, MD

Şuayib Yalçın, MD, Ömer Dizdar, MD, Başak Yalçın, MD, Özay Gököz, MD

Donna M. Hepper, MD, Peggy Wu, MD, Milan J. Anadkat, MD

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis Tsung-Yu Tsai, MD, Yu-Chen Huang, MD Journal.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Fever, eosinophilia, and a rash

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Infectious rash after riding elephants

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Lip edema Journal of the American Academy of Dermatology

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

George Blumenschein, MD, John V. Heymach, MD, PhD

Clinical courses of patients.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Hugh Gloster, MD, Chesahna Kindred, MBA

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Simple onycholysis: A diagnosis of exclusion

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Descriptive survival study of nail melanoma patients treated with functional surgery versus distal amputation Suelen Montagner, MD, Francisco Aparecido.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Lisa A. Beck, MD, Sarbjit Saini, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

The JAAD adopts the CONSORT statement

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

A Review of First-Line Treatment for Small-cell Lung Cancer

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Presentation transcript:

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer Yoshio Kiyohara, MD, Naoya Yamazaki, MD, Akiko Kishi, MD Journal of the American Academy of Dermatology Volume 69, Issue 3, Pages 463-472 (September 2013) DOI: 10.1016/j.jaad.2013.02.025 Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Rash emergence, severity, and survival. Relationship between these in BR.21 study.11 CI, Confidence interval; HR, hazard ratio. Reprinted from Clinical Cancer Research 2007;13(13):3913-22, Wacker B et al, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies, with permission from AACR. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Acneiform rash and xeroderma. Characteristic symptoms. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Paronychia. Characteristic symptoms. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Grade ≥2 skin toxicity in patients with metastatic colorectal cancer (Skin Toxicity Evaluation Protocol with Panitumumab [STEPP] study), time to first occurrence.21 CI, Confidence interval; NR, not reached. Reprinted from Lacouture ME et al, Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer, Journal of Clinical Oncology 28(8):1351-7, with permission. © (2010) American Society of Clinical Oncology. All rights reserved. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 5 Erlotinib-related skin disorders. Diagnosis and treatment. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 6 Application of topical creams and emollients: guidance on quantities for application. FTU, Fingertip unit. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 7 Procedure for using tape to treat paronychia. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 8 Procedure for removing nail plate and matrix in cases of paronychia. Journal of the American Academy of Dermatology 2013 69, 463-472DOI: (10.1016/j.jaad.2013.02.025) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions